To do so, we evaluated the expression of activation markers CD39+ and CD69+ on the CAR‐T cell product (Figure 5A) as well as on CAR T cells isolated from tumour and spleen of treated mice at day 40, post treatment (Figure 5B–G). The gene discussed is CD69; the disease is neoplasm.